Related references
Note: Only part of the references are listed.SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Xiaoying Shen et al.
CELL HOST & MICROBE (2021)
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
Kai Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
Laurence Chu et al.
VACCINE (2021)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
David S. Khoury et al.
NATURE MEDICINE (2021)
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
S. A. Madhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Nicole Doria-Rose et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
V. Shinde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Ali Pormohammad et al.
VACCINES (2021)
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
Jackson S. Turner et al.
NATURE (2021)
An mRNA Vaccine against SARS-CoV-2-Preliminary Report
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
E. J. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines
Michael A. Whitt
JOURNAL OF VIROLOGICAL METHODS (2010)